Pfizer and BioNTech's Coronavirus Vaccine Approved in Europe

Fresh off receiving its crucial emergency use authorization (EUA) in the U.S., Pfizer (NYSE:PFE) and BioNTech's (NASDAQ:BNTX) coronavirus vaccine has received similar approval in Europe.

Both companies announced Monday that their BNT162b2 -- which will also be known in Europe under the brand name Comirnaty -- has received conditional marketing authorization (CMA) from the European Commission (EC) for patients aged 16 and older.